PDS Biotechnology Corporation (PDSB) has announced the presentation of the rationale and trial design for a study evaluating PDS01ADC in treating recurrent prostate cancer. The presentation occurred at the 12th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2024) in Seoul, South Korea.
The presentation, delivered by Ravi A. Madan, M.D., Head of the Prostate Cancer Clinical Research Section at the National Cancer Institute, detailed a clinical trial combining PDS01ADC, a tumor-targeting immunocytokine, with enzalutamide, an androgen receptor pathway inhibitor, in patients with biochemically recurrent prostate cancer. Notably, the trial will proceed without testosterone-lowering therapy.
PDS01ADC is an IL-12 fused antibody-drug conjugate (ADC). PDS Biotech's broader strategy involves developing Versamune® HPV, a targeted immunotherapy, in combination with immune checkpoint inhibitors, and also in a triple combination including PDS01ADC and a standard-of-care immune checkpoint inhibitor.
PDS Biotechnology is focused on developing immunotherapies and infectious disease vaccines. The company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers.
